CoChat
Sign Up
Cited by 662

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

Musiek, Erik S, Holtzman, David M·2015·Nature Neuroscience
DOI 10.1038/nn.4018PMC PMC4445458
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nn.4018

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 83

  1. Hardy, J.A. & Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992). · DOI · Paper page
  2. Bettens, K., Sleegers, K. & Van Broeckhoven, C. Genetic insights in Alzheimer's disease. Lancet Neurol. 12, 92–104 (2013). · DOI · Paper page
  3. Levy, E. et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124–1126 (1990). · DOI
  4. Tsubuki, S., Takaki, Y. & Saido, T.C. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 361, 1957–1958 (2003). · DOI
  5. Tomiyama, T. et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann. Neurol. 63, 377–387 (2008). · DOI
  6. Rovelet-Lecrux, A. et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38, 24–26 (2006). · DOI
  7. Sleegers, K. et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129, 2977–2983 (2006). · DOI
  8. Cabrejo, L. et al. Phenotype associated with APP duplication in five families. Brain 129, 2966–2976 (2006). · DOI
  9. Prasher, V.P. et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann. Neurol. 43, 380–383 (1998). · DOI · Paper page
  10. Eckman, C.B. et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum. Mol. Genet. 6, 2087–2089 (1997). · DOI · Paper page
  11. Chávez-Gutiérrez, L. et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261–2274 (2012). · DOI · Paper page
  12. Shepherd, C., McCann, H. & Halliday, G.M. Variations in the neuropathology of familial Alzheimer's disease. Acta Neuropathol. 118, 37–52 (2009). · DOI
  13. Ryman, D.C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253–260 (2014). · DOI · Paper page
  14. Corder, E.H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921–923 (1993). · DOI · Paper page
  15. Verghese, P.B. et al. ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions. Proc. Natl. Acad. Sci. USA 110, E1807–E1816 (2013). · DOI · Paper page
  16. Sunderland, T. et al. Cerebrospinal fluid beta-amyloid1–42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol. Psychiatry 56, 670–676 (2004). · DOI · Paper page
  17. Arriagada, P.V., Marzloff, K. & Hyman, B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 42, 1681–1688 (1992). · DOI · Paper page
  18. Price, J.L., Davis, P.B., Morris, J.C. & White, D.L. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging 12, 295–312 (1991). · DOI · Paper page
  19. Price, J.L. & Morris, J.C. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 45, 358–368 (1999). · DOI
  20. Elobeid, A., Soininen, H. & Alafuzoff, I. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol. 123, 97–104 (2012). · DOI
  21. Knopman, D.S. et al. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62, 1087–1095 (2003). · DOI · Paper page
  22. Petersen, R.C. et al. Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. 63, 665–672 (2006). · DOI · Paper page
  23. Tiraboschi, P., Hansen, L.A., Thal, L.J. & Corey-Bloom, J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984–1989 (2004). · DOI · Paper page
  24. Reed, L.A. et al. Autosomal dominant dementia with widespread neurofibrillary tangles. Ann. Neurol. 42, 564–572 (1997). · DOI
  25. Lindquist, S.G. et al. Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. Eur. J. Neurol. 15, 377–385 (2008). · DOI
  26. Kauwe, J.S. et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc. Natl. Acad. Sci. USA 105, 8050–8054 (2008). · DOI
  27. Ferreira, A., Lu, Q., Orecchio, L. & Kosik, K.S. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol. Cell. Neurosci. 9, 220–234 (1997). · DOI · Paper page
  28. Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P. & Ferreira, A. Tau is essential to beta -amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 99, 6364–6369 (2002). · DOI · Paper page
  29. Jin, M. et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. USA 108, 5819–5824 (2011). · DOI · Paper page
  30. Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487–1491 (2001). · DOI · Paper page
  31. Götz, J., Chen, F., van Dorpe, J. & Nitsch, R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491–1495 (2001). · DOI · Paper page
  32. Roberson, E.D. et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750–754 (2007). · DOI · Paper page
  33. Roberson, E.D. et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700–711 (2011). · DOI · Paper page
  34. Hashimoto, M. & Masliah, E. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 9, 707–720 (1999). · DOI
  35. Larson, M.E. et al. Soluble alpha-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J. Neurosci. 32, 10253–10266 (2012). · DOI · Paper page
  36. Josephs, K.A. et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol. 127, 811–824 (2014). · DOI · Paper page
  37. Jack, C.R. Jr. et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216 (2013). · DOI · Paper page
  38. Jack, C.R. Jr. et al. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. 68, 1526–1535 (2011). · DOI
  39. Roe, C.M. et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80, 1784–1791 (2013). · DOI · Paper page
  40. Villemagne, V.L. et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357–367 (2013). · DOI · Paper page
  41. Chen, X. et al. Pittsburgh compound B retention and progression of cognitive status–a meta-analysis. Eur. J. Neurol. 21, 1060–1067 (2014). · DOI
  42. Knopman, D.S. et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78, 1576–1582 (2012). · DOI
  43. Tarawneh, R. et al. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann. Neurol. 70, 274–285 (2011). · DOI
  44. Donohue, M.C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961–970 (2014). · DOI · Paper page
  45. Chételat, G. et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 78, 477–484 (2012). · DOI
  46. Mucke, L. & Selkoe, D.J. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2, a006338 (2012). · DOI · Paper page
  47. Esparza, T.J. et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73, 104–119 (2013). · DOI
  48. McLean, C.A. et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860–866 (1999). · DOI
  49. Lesné, S.E. et al. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 136, 1383–1398 (2013). · DOI
  50. Handoko, M. et al. Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol. 70, 594–599 (2013). · DOI
  51. Zhang, Y. et al. A lifespan observation of a novel mouse model: in vivo evidence supports abeta oligomer hypothesis. PLoS ONE 9, e85885 (2014). · DOI
  52. Ma, Q.L. et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29, 9078–9089 (2009). · DOI · Paper page
  53. Ittner, L.M. et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142, 387–397 (2010). · DOI · Paper page
  54. Haass, C. & Mandelkow, E. Fyn-tau-amyloid: a toxic triad. Cell 142, 356–358 (2010). · DOI
  55. Zhang, Z. et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat. Med. 20, 1254–1262 (2014). · DOI · Paper page
  56. Sanders, D.W. et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82, 1271–1288 (2014). · DOI · Paper page
  57. Liu, L. et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302 (2012). · DOI
  58. Guo, J.L. et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103–117 (2013). · DOI · Paper page
  59. Dasuri, K., Zhang, L. & Keller, J.N. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic. Biol. Med. 62, 170–185 (2013). · DOI · Paper page
  60. Nixon, R.A. & Yang, D.S. Autophagy failure in Alzheimer's disease–locating the primary defect. Neurobiol. Dis. 43, 38–45 (2011). · DOI · Paper page
  61. Lu, T. et al. REST and stress resistance in ageing and Alzheimer's disease. Nature 507, 448–454 (2014). · DOI
  62. Benzing, W.C. et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging 20, 581–589 (1999). · DOI
  63. Calkins, M.J., Manczak, M., Mao, P., Shirendeb, U. & Reddy, P.H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum. Mol. Genet. 20, 4515–4529 (2011). · DOI · Paper page
  64. Guix, F.X. et al. Modification of gamma-secretase by nitrosative stress links neuronal ageing to sporadic Alzheimer's disease. EMBO Mol. Med. 4, 660–673 (2012). · DOI
  65. Wahlster, L. et al. Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease. Acta Neuropathol. 125, 187–199 (2013). · DOI
  66. Kukreja, L., Kujoth, G.C., Prolla, T.A., Van Leuven, F. & Vassar, R. Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer's disease. Mol. Neurodegener. 9, 16 (2014). · DOI
  67. Liu, Y. et al. IKKbeta deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology. J. Neurosci. 34, 12982–12999 (2014). · DOI
  68. Durazzo, T.C., Mattsson, N. & Weiner, M.W. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. Alzheimers Dement. 10, S122–S145 (2014). · DOI
  69. Moreno-Gonzalez, I., Estrada, L.D., Sanchez-Mejias, E. & Soto, C. Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. Nat. Commun. 4, 1495 (2013). · DOI
  70. Cady, J. et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 71, 449–453 (2014). · DOI · Paper page
  71. Melnikova, T. et al. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J. Neurosci. 33, 3765–3779 (2013). · DOI
  72. Berger-Sweeney, J. et al. Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. Brain Res. Mol. Brain Res. 66, 150–162 (1999). · DOI
  73. Gao, Y. & Pimplikar, S.W. The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc. Natl. Acad. Sci. USA 98, 14979–14984 (2001). · DOI
  74. Zheng, H. & Koo, E.H. Biology and pathophysiology of the amyloid precursor protein. Mol. Neurodegener. 6, 27 (2011). · DOI
  75. Bero, A.W. et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat. Neurosci. 14, 750–756 (2011). · DOI · Paper page
  76. Kang, J.E. et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 1005–1007 (2009). · DOI · Paper page
  77. Siegel, S.J., Bieschke, J., Powers, E.T. & Kelly, J.W. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46, 1503–1510 (2007). · DOI
  78. Head, E. et al. Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol. Dis. 8, 792–806 (2001). · DOI · Paper page
  79. Zhao, W., Zhang, J., Davis, E.G. & Rebeck, G.W. Aging reduces glial uptake and promotes extracellular accumulation of Abeta from a lentiviral vector. Front. Aging Neurosci. 6, 210 (2014).
  80. Hipp, M.S., Park, S.H. & Hartl, F.U. Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol. 24, 506–514 (2014). · DOI
  81. Vellas, B. et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144–151 (2009). · DOI
  82. Mills, S.M. et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev. Neurol. (Paris) 169, 737–743 (2013). · DOI
  83. Reiman, E.M. et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26 (suppl. 3), 321–329 (2011). · DOI

Cited by

Sorted by citations

Metadata

Authors
Musiek, E. S., & Holtzman, D. M.
Venue
Nature Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2015-05-26
Volume
18
Issue
6
Pages
800-806
ISSN
  • 1097-6256
  • 1546-1726
DOI
10.1038/nn.4018
PMC
PMC4445458
Cited by
662
References
52
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review